These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37899631)

  • 1. Correction to "Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting".
    Clin Pharmacol Ther; 2023 Dec; 114(6):1387. PubMed ID: 37899631
    [No Abstract]   [Full Text] [Related]  

  • 2. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
    Downing NS; Shah ND; Aminawung JA; Pease AM; Zeitoun JD; Krumholz HM; Ross JS
    JAMA; 2017 May; 317(18):1854-1863. PubMed ID: 28492899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting.
    Schotland P; Racz R; Jackson DB; Soldatos TG; Levin R; Strauss DG; Burkhart K
    Clin Pharmacol Ther; 2021 May; 109(5):1232-1243. PubMed ID: 33090463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics.
    Eadie A; MacGregor A; Wallach J; Ross J; Herder M
    BMJ Evid Based Med; 2023 Jun; 28(3):151-156. PubMed ID: 36944478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States.
    Bhasale AL; Sarpatwari A; De Bruin ML; Lexchin J; Lopert R; Bahri P; Mintzes BJ
    Clin Pharmacol Ther; 2021 Jun; 109(6):1424-1442. PubMed ID: 32767557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors.
    Abboud CN; Lang N; Fung H; Lammerich A; Buchner A; Liu P; Mueller U; Pettengell R; Diel IJ; Link H; Pathak A
    Support Care Cancer; 2019 Jul; 27(7):2569-2577. PubMed ID: 30443809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the quality and value of data sources for postmarket surveillance of the safety of cough and cold medications in children.
    Green JL; Reynolds KM; Banner W; Bond GR; Kauffman RE; Palmer RB; Paul IM; Dart RC
    BMC Med Res Methodol; 2018 Dec; 18(1):175. PubMed ID: 30577764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarket Assessment for Drugs and Biologics Used in Dermatology and Cutaneous Adverse Drug Reactions.
    Reyes M; Kortepeter C; Muñoz M
    Dermatol Clin; 2022 Jul; 40(3):265-277. PubMed ID: 35750410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study.
    Lexchin J
    BMJ Open; 2014 Feb; 4(2):e004289. PubMed ID: 24549164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target-Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities.
    Schotland P; Racz R; Jackson D; Levin R; Strauss DG; Burkhart K
    CPT Pharmacometrics Syst Pharmacol; 2018 Dec; 7(12):809-817. PubMed ID: 30354029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Postmarket Surveillance to Assess Safety-Related Events in a Digital Rehabilitation App (Kaia App): Observational Study.
    Jain D; Norman K; Werner Z; Makovoz B; Baker T; Huber S
    JMIR Hum Factors; 2021 Nov; 8(4):e25453. PubMed ID: 34751664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
    Samuel AM; Rathi VK; Grauer JN; Ross JS
    Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six Years of the US Food and Drug Administration's Postmarket Active Risk Identification and Analysis System in the Sentinel Initiative: Implications for Real World Evidence Generation.
    Maro JC; Nguyen MD; Kolonoski J; Schoeplein R; Huang TY; Dutcher SK; Dal Pan GJ; Ball R
    Clin Pharmacol Ther; 2023 Oct; 114(4):815-824. PubMed ID: 37391385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower Proportion of Spontaneous Adverse Event Reports for Generic Drugs by Comparison With Original Branded Drugs at the Postmarket Stage in Japan.
    Takami A; Hirata K; Ishiguro C; Hanaoka H; Uyama Y
    Clin Pharmacol Ther; 2019 Jun; 105(6):1471-1476. PubMed ID: 30588617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
    JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reporting of Death in US Food and Drug Administration Medical Device Adverse Event Reports in Categories Other Than Death.
    Lalani C; Kunwar EM; Kinard M; Dhruva SS; Redberg RF
    JAMA Intern Med; 2021 Sep; 181(9):1217-1223. PubMed ID: 34309624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comprehensive Analysis of Postmarket Surveillance Study Orders: Device Characteristics, Study Statuses, Outcomes, and Potential Contributions.
    Iwaishi C; Iwasaki K
    Ther Innov Regul Sci; 2020 Jul; 54(4):953-963. PubMed ID: 31997227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions.
    Lu Z; Suzuki A; Wang D
    BMC Med Res Methodol; 2023 Mar; 23(1):71. PubMed ID: 36973693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.